Synthetic Long Peptides (SLPs) Based Neoantigen Cancer Vaccines

Creative Biolabs brings together the world's top vaccine development teams with state-of-the-art facilities, equipment, and highly trained laboratory staff. We have over 10 years of experience in vaccine development. In the field of cancer vaccine development, we specialize in the development of various types of cancer vaccines including antigen vaccines, vectored vaccines, nucleic acid vaccines, and dendritic cell vaccines, etc.

Background

Activation of the human immune system to prevent and treat infections or other diseases is of great significance to human health, and vaccines are an invention that makes this sense. Choosing the appropriate and effective antigen is the key to developing a successful vaccine. The reason why most vaccines have little significant efficacy compared with immunological checkpoint inhibitors and adoptive T-cell therapies is also at this point. Traditional cancer vaccines target tumor-associated antigens that are overexpressed in cancer cells and expressed in small amounts in normal cells, although targeting this antigen may serve as a universal target, but may cause central or peripheral tolerance. This, in turn, limits the effectiveness of the vaccine or causes the vaccine to be autoimmune to normal tissues.

SLP-based Neoantigen Cancer Vaccines

Neoantigen is a tumor-specific antigen produced by random mutations in tumor cells and is not present on normal cells, which makes it superior to TAAs targeting vaccine in terms of specificity, efficacy, and safety. The immunogenicity test also showed the potency of neoantigen. Because of the specificity of neoantigen for cancer cells and their potential for anti-tumor, a series of neoantigen-based cancer vaccine development strategies have been proposed and validated, and synthetic long peptides (SLPs) are one of them. Antigenic peptides can function directly as T cell epitopes, with low toxicity, simple synthesis, and low production cost. These advantages make them an ideal option for cancer vaccines. And, gratifyingly, clinical trials in patients with advanced cutaneous melanoma have shown that vaccination with SLP-based neoantigen cancer vaccines can induce versatile CD4⁺ T responses and CD8⁺ T cells responses. Moreover, two-thirds of the subjects did not develop cancer after 25 months of treatment.

Our Services for Development of SLP-based Neoantigen Cancer Vaccines

• Prediction of immunogenic neoantigens as well as epitopes
• GMP-compliant peptide synthesis
• Adjuvant selection and optimization
• Formulation and delivery method development
• Evaluation and data analysis of efficacy and safety of vaccine candidate

In order to develop successful cancer vaccines, Creative Biolabs has absorbed a number of cutting-edge discoveries and is actively transforming them into available technologies and platforms. We have prepared a series of one-stop services for the development of synthetic long peptides based neoantigen cancer vaccines. If you have any needs, please contact us!

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.